CDI 2nd Annual User Group Meeting (Aug 26 – 28, Madison, WI). Discuss recent innovations using iPSC-derived cells in discovery, toxicity, disease research, and tissue engineering at our upcoming User Group Meeting. Confirmed speakers include:
- Keynote – Dr. Leroy Hood, Institute for Systems Biology
- Anne Bang, Sanford Burnham
- M. Eileen Dolan, University of Chicago
- James Hickman, University of Central Florida
- Salman Khetani, Colorado State University
- Jonathan Lee, Eli Lilly
- Dinah Misner, Genentech
- William Murphy, University of Wisconsin – Madison
- Matt Peters, AstraZeneca
- Sharon Presnell, Organovo
- Sonia Santos, Pfizer/Neusentis
- Miriam Triyatni, Hoffmann-La Roche
- Yvonne Will, Pfizer
xCELLigence Cardio User Symposium (Jul 12 – 13, Arlington, VA). Join us at the following session:
- Arrhythmia and QT Prolongation Prediction Using iCell Cardiomyocytes: Past, Present, and Future
Jul 13 | 10:50 – 11:25 am
Cell Symposia: Using Stem Cells to Model and Treat Human Disease (Nov 21 – 23, Los Angeles, CA). Submit your abstract by Jul 19 for this meeting sponsored by CDI.
Human-induced Pluripotent Stem Cell-derived Cardiomyocytes for Studies of Cardiac Ion Transporters. Researchers at the University of Texas Southwestern Medical School at Dallas show that cardiac ion transporters in iCell Cardiomyocytes are similar in expression levels and activity to adult non-rodent cardiomyocytes. Various cellular techniques, including Halo® fusion proteins, were used to demonstrate native ion transporter function and modulation through small molecules and regulatory proteins in iCell Cardiomyocytes.
Fine M, Lu F-M, Lin M-J, Moe OW, Wang H-R, and Hilgemann DW (2013) Am J Physiol Cell Physiol. Epub ahead of print (DOI: 10.1152/ajpcell.00143.2013).
Japan-US Innovation Awards: Bloom Energy and Cellular Dynamics Named Co-winners. The Japan – US Innovation Awards program selected CDI as co-winner of the 2013 Emerging Leader – US Award. CDI was chosen from 60+ nominees for its leadership in mass producing human iPSC lines and tissue cells, transforming drug discovery, toxicity testing, therapeutic research, and stem cell banking.
Takara Bio Grants Cellular Dynamics International a Commercial License to Use RetroNectin® for iPSC Production. This agreement allows CDI to use RetroNectin as one of its tools for the development and manufacture of iCell and MyCell products. RetroNectin is a recombinant human fibronectin fragment that increases efficiency in retrovirus mediated gene transduction.